Extrahepatic Lipid-Based Nanoparticles Delivery Summit on June 02-04, 2026 in Boston, United States

Achieving precise extrahepatic delivery remains one of the biggest challenges in the LNP field. However, with AbbVie’s acquisition of Capstan Therapeutics and BMS’s acquisition of Orbital Therapeutics, the industry’s confidence in targeted LNPs has never been higher!

Returning to Boston in June 2026, the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit is bringing together industry pioneers and leading delivery experts to showcase the latest advances in novel targeting ligands and innovative lipid-based technologies. Across 3 jam-packed days, attendees will gain in-depth technical insights into accelerating the delivery of mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, adipose tissues, muscle, and more.

With world-class speakers from the likes of AbbVie, AstraZeneca, Novartis, Mote Therapeutics, Strand Therapeutics, and more, this is your premium opportunity to stay at the cutting-edge of extrahepatic targeting as well as collectively overcome challenges in targeted LNP analytics, scalability, and immunogenicity. Join this expert-led forum dedicated solely to delivery outside the liver and accelerate cell-specific LNPs towards the clinic.

URLs:

Tickets: https://go.evvnt.com/3461726-2?pid=10008

Brochure: https://go.evvnt.com/3461726-3?pid=10008

Time: 8:00 AM - 6:00 PM

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 3397.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 2998.00,

Drug Developer Pricing - Conference Only: USD 2599.00,

Academic Pricing - Conference + 2 Workshops: USD 2797.00,

Academic Pricing - Conference + 1 Workshop: USD 2498.00,

Academic Pricing - Conference Only: USD 2199.00,

Service Provider Pricing - Conference + 2 Workshops: USD 4297.00,

Service Provider Pricing - Conference + 1 Workshop: USD 3798.00,

Service Provider Pricing - Conference Only: USD 3299.00

Speakers: Atip Lawanprasert, Postdoctoral Fellow, Murthy Lab, University of California at Berkeley, Bohdan Andreiuk, Senior Scientist, New Modality Preformulation, AstraZeneca, Cangjie Yang, Associate Director, Zipcode Bio, Chi Zhang, Co-Founder and Chief Scientific Officer, GT Biosciences, Christopher, Geisert Associate Scientist, Nucleic Acid Process Development and Delivery, Stylus Medicine, Emily Gosselin, Senior Scientist, Corner Therapeutics, Gilles Divita, Chief Executive and Scientific Officer, Aanastra Inc, Hongjing Xia, Principal Scientist, Novartis AG, James Carroll, President and Chief Scientific Officer, RNA Nanobiotics, Jessica Kenison-White, Scientific Director, Immunocodex, Jieni Xu, Head of Delivery Sciences, Editas Medicine, Justin Fang, Senior Scientist, Formulations, Mote Therapeutics, Kanika Suri, Drug Product Device Development, CMC Scientist, Scientist, Ketaki Deshmukh, Senior Scientist, Novo Nordisk, Neha Kapate, Senior Scientist I, Immune Tolerance, Abbvie, Pintu Kanjilal, Scientist, LNP Discovery, Strand Therapeutics Inc., Raj Reddy, Chief Executive Officer, Canary Cure Therapeutics, Russell Johnson, Executive Director, Delivery Sciences, Moderna, Sandipan Dawn, Principal Scientist, Foghorn Therapeutics, Sanjib Saha, Senior Scientist, Advanced Drug Delivery, AstraZeneca, Soultan Al-Halifa, Director, Feldan Therapeutics, Subhadeep Dutta, Senior Scientist, Discovery Pharmaceutical Sciences, Merck and Co, Venkat Krishnamurthy, Chief Scientific Officer, Flashpoint Therapeutics